Co-targeting the PI3K/AKT pathway alongside strategies to boost PHLDA3 levels may yield synergistic effects, and exploring its role in immuno-oncology could provide new insights into tumor immune evasion and response to immunotherapy. Here, AKT1 is linked to neoplasm.